OGN

Organon & Co.

Halal Rating :
Uncomfortable
See Details
Last Price $15.03 Last updated:
Market Cap $4.84b
7D Change -6.3%
1 Year Change 37.26%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NYSE
Next Earnings Date Oct. 31, 2024

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $1.58b $1.37b - $126.0m 0.00% 9.20%
June 30, 2024 $1.61b $1.37b - $131.0m 0.00% 9.58%
March 31, 2024 $1.62b $1.38b - $131.0m 0.00% 9.51%

Company Impact

Help us evaluate Organon & Co.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Justification for our Halal Rating

Contribute

Recent News & Updates